↓ Skip to main content

Timing of therapies for Down syndrome: the sooner, the better

Overview of attention for article published in Frontiers in Behavioral Neuroscience, October 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
4 news outlets
twitter
7 X users

Citations

dimensions_citation
100 Dimensions

Readers on

mendeley
188 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Timing of therapies for Down syndrome: the sooner, the better
Published in
Frontiers in Behavioral Neuroscience, October 2015
DOI 10.3389/fnbeh.2015.00265
Pubmed ID
Authors

Fiorenza Stagni, Andrea Giacomini, Sandra Guidi, Elisabetta Ciani, Renata Bartesaghi

Abstract

Intellectual disability (ID) is the unavoidable hallmark of Down syndrome (DS), with a heavy impact on public health. Accumulating evidence shows that DS is characterized by numerous neurodevelopmental alterations among which the reduction of neurogenesis, dendritic hypotrophy and connectivity alterations appear to play a particularly prominent role. Although the mechanisms whereby gene triplication impairs brain development in DS have not been fully clarified, it is theoretically possible to correct trisomy-dependent defects with targeted pharmacotherapies. This review summarizes what we know about the effects of pharmacotherapies during different life stages in mouse models of DS. Since brain alterations in DS start to be present prenatally, the prenatal period represents an optimum window of opportunity for therapeutic interventions. Importantly, recent studies clearly show that treatment during the prenatal period can rescue overall brain development and behavior and that this effect outlasts treatment cessation. Although late therapies are unlikely to exert drastic changes in the brain, they may have an impact on the hippocampus, a brain region where neurogenesis continues throughout life. Indeed, treatment at adult life stages improves or even rescues hippocampal neurogenesis and connectivity and hippocampal-dependent learning and memory, although the duration of these effects still remains, in the majority of cases, a matter of investigation. The exciting discovery that trisomy-linked brain abnormalities can be prevented with early interventions gives us reason to believe that treatments during pregnancy may rescue brain development in fetuses with DS. For this reason we deem it extremely important to expedite the discovery of additional therapies practicable in humans in order to identify the best treatment/s in terms of efficacy and paucity of side effects. Prompt achievement of this goal is the big challenge for the scientific community of researchers interested in DS.

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 188 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
Netherlands 1 <1%
Unknown 186 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 40 21%
Researcher 29 15%
Student > Bachelor 26 14%
Student > Master 20 11%
Other 13 7%
Other 29 15%
Unknown 31 16%
Readers by discipline Count As %
Neuroscience 34 18%
Biochemistry, Genetics and Molecular Biology 28 15%
Agricultural and Biological Sciences 28 15%
Medicine and Dentistry 18 10%
Psychology 12 6%
Other 29 15%
Unknown 39 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 39. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 August 2022.
All research outputs
#897,678
of 23,056,273 outputs
Outputs from Frontiers in Behavioral Neuroscience
#135
of 3,206 outputs
Outputs of similar age
#14,333
of 278,539 outputs
Outputs of similar age from Frontiers in Behavioral Neuroscience
#4
of 86 outputs
Altmetric has tracked 23,056,273 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,206 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.3. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 278,539 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 86 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.